Boston Scientific Corporation $BSX Holdings Boosted by Goelzer Investment Management Inc.

Goelzer Investment Management Inc. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 287.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 49,215 shares of the medical equipment provider’s stock after acquiring an additional 36,524 shares during the period. Goelzer Investment Management Inc.’s holdings in Boston Scientific were worth $2,148,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Activest Wealth Management grew its stake in shares of Boston Scientific by 202.6% in the 3rd quarter. Activest Wealth Management now owns 1,831 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 1,226 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Boston Scientific by 26.4% in the third quarter. V Square Quantitative Management LLC now owns 14,164 shares of the medical equipment provider’s stock valued at $618,000 after purchasing an additional 2,956 shares during the period. Community Trust & Investment Co. increased its holdings in shares of Boston Scientific by 6.9% in the third quarter. Community Trust & Investment Co. now owns 221,836 shares of the medical equipment provider’s stock valued at $9,683,000 after purchasing an additional 14,258 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Boston Scientific by 61.5% during the third quarter. Assenagon Asset Management S.A. now owns 6,740,683 shares of the medical equipment provider’s stock worth $295,377,000 after purchasing an additional 2,567,124 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its stake in shares of Boston Scientific by 11.8% during the third quarter. State of Alaska Department of Revenue now owns 162,750 shares of the medical equipment provider’s stock worth $7,104,000 after purchasing an additional 17,115 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.5%

BSX opened at $44.34 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $64.26 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 1.07 and a beta of 0.58. Boston Scientific Corporation has a one year low of $41.38 and a one year high of $105.65. The business’s fifty day moving average is $46.06 and its two-hundred day moving average is $49.76.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David Habiger acquired 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Edward Ludwig bought 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of several recent research reports. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Argus reiterated a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Rothschild & Co Redburn dropped their price objective on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, BTIG Research lowered their target price on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.